| [1] | Molitch ME. Diagnosis and treatment of pituitary adenomas[J]. JAMA, 2017, 317(5): 516-524. doi: 10.1001/jama.2016.19699    
																																																	pmid: 28170483
 | 
																													
																							| [2] | Melmed S. Pituitary-tumor endocrinopathies[J]. N Engl J Med, 2020, 382(10): 937-950. doi: 10.1056/NEJMra1810772    
																																					URL
 | 
																													
																							| [3] | Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing’s disease[J]. Lancet Diabetes Endocrinol, 2021, 9(12): 847-875. doi: 10.1016/S2213-8587(21)00235-7    
																																					URL
 | 
																													
																							| [4] | Reincke M, Sbiera S, Hayakawa A, et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease[J]. Nat Genet, 2015, 47(1): 31-38. doi: 10.1038/ng.3166    
																																																	pmid: 25485838
 | 
																													
																							| [5] | Ma ZY, Song ZJ, Chen JH, et al. Recurrent gain-of-function USP8 mutations in Cushing’s disease[J]. Cell Res, 2015, 25(3): 306-317. doi: 10.1038/cr.2015.20
 | 
																													
																							| [6] | Castellnou S, Vasiljevic A, Lapras V, et al. SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors[J]. Endocr Connect, 2020, 9(3): 243-253. doi: 10.1530/EC-20-0035    
																																					URL
 | 
																													
																							| [7] | Chen J, Jian X, Deng S, et al. Identification of recurrent USP48 and BRAF mutations in Cushing’s disease[J]. NNat Commun, 2018, 9(1): 3171. | 
																													
																							| [8] | Hernández-Ramírez LC, Gam R, Valdés N, et al. Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing’s disease[J]. Endocr Relat Cancer, 2017, 24(8): 379-392. doi: 10.1530/ERC-17-0131    
																																					URL
 | 
																													
																							| [9] | Schernthaner-Reiter MH, Trivellin G, Stratakis CA. MEN1, MEN4, and carney complex: pathology and molecular genetics[J]. Neuroendocrinology, 2016, 103(1): 18-31. doi: 10.1159/000371819    
																																																	pmid: 25592387
 | 
																													
																							| [10] | Chasseloup F, Pankratz N, Lane J, et al. Germline CDKN1B loss-of-function variants cause pediatric Cushing’s disease with or without an MEN4 phenotype[J]. J Clin Endocrinol Metab, 2020, 105(6): 1983-2005. doi: 10.1210/clinem/dgaa160    
																																					URL
 | 
																													
																							| [11] | Mete O, Lopes MB. Overview of the 2017 WHO classification of pituitary tumors[J]. Endocr Pathol, 2017, 28(3): 228-243. doi: 10.1007/s12022-017-9498-z    
																																																	pmid: 28766057
 | 
																													
																							| [12] | Asa SL, Mete O, Perry A, et al. Overview of the 2022 WHO classification of pituitary tumors[J]. Endocr Pathol, 2022, 33(1): 6-26. doi: 10.1007/s12022-022-09703-7    
																																																	pmid: 35291028
 | 
																													
																							| [13] | WHO Classification of Tumours Editorial Board. WHO classification of endocrine and neuroendocrine tumours[M]. Lyon: IARC Press, 2022. | 
																													
																							| [14] | Reincke M, Theodoropoulou M. Genomics in Cushing’s disease: the dawn of a new era[J]. J Clin Endocrinol Metab, 2021, 106(6): e2455-e2456. doi: 10.1210/clinem/dgaa969    
																																																	pmid: 33524136
 |